Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE PAOLI-BRUNO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1982601159
CMS profile
419826
Location
MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$120.40

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $120.40 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan Inc. $120.40 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE PAOLI-BRUNO

NPI 1982601159 · CMS profile ID 419826

Allopathic & Osteopathic Physicians / Family Medicine

MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $120.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $120.4010/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670916157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $961,612.31 249
PY2024 Recipient $4,214.80 1
PY2024 Principal investigator $2,148,310.31 277
PY2023 Principal investigator $1,000,560.67 172
PY2022 Recipient $253.00 2
PY2022 Principal investigator $730,831.67 34
PY2021 Recipient $1,654.33 2
PY2021 Principal investigator $437,077.46 64
PY2020 Recipient $2,885.98 3
PY2020 Principal investigator $359,635.45 60
PY2019 Principal investigator $605,972.33 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

172 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Chiesi USA, Inc. $9,111.00 12/13/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051619435
Principal investigator 1 GlaxoSmithKline, LLC. $3,118.50 12/13/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127784801
Principal investigator 1 GlaxoSmithKline, LLC. $4,649.40 12/06/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127784803
Principal investigator 1 IBSA Institut Biochimique SA $9,000.00 11/24/2023 Non-covered Recipient Entity
PCRS NETWORK LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1005351993
Principal investigator 1 GlaxoSmithKline, LLC. $4,327.20 11/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006263069
Principal investigator 1 Chiesi USA, Inc. $454.00 11/07/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051616621
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613087
Principal investigator 1 Chiesi USA, Inc. $6,120.51 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613093
Principal investigator 1 Chiesi USA, Inc. $415.13 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613099
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613107
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613113
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613119
Principal investigator 1 Chiesi USA, Inc. $415.13 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613125
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613131
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613137
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613143
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613149
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613155
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613163
Principal investigator 1 Chiesi USA, Inc. $6,120.51 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613167
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613173
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613179
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613185
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613193
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613199
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613203
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613211
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613217
Principal investigator 1 Chiesi USA, Inc. $6,120.51 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613223
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613229
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613235
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613239
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613245
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613251
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613257
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613261
Principal investigator 1 Chiesi USA, Inc. $415.13 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613265
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613273
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613277
Principal investigator 1 Chiesi USA, Inc. $6,120.51 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613282
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613287
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613291
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613297
Principal investigator 1 Chiesi USA, Inc. $1,214.73 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613303
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613309
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613315
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613321
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613327
Principal investigator 1 Chiesi USA, Inc. $2,492.08 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613333
Principal investigator 1 Chiesi USA, Inc. $1,776.59 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613339
Principal investigator 1 Chiesi USA, Inc. $5,962.40 10/30/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051613345
Principal investigator 1 Chiesi USA, Inc. $40,281.00 10/26/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051612747
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 10/13/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 1035805459
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,150.14 10/13/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 1035805471
Principal investigator 1 PFIZER INC. $2,693.34 10/12/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1045966935
Principal investigator 1 Eli Lilly and Company $11,574.00 10/10/2023 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1038097565
Principal investigator 1 CIPLA USA INC. $1,891.45 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139613
Principal investigator 1 CIPLA USA INC. $1,188.00 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139619
Principal investigator 1 CIPLA USA INC. $1,517.17 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139625
Principal investigator 1 CIPLA USA INC. $3,813.48 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139877
Principal investigator 1 CIPLA USA INC. $1,940.99 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139885
Principal investigator 1 CIPLA USA INC. $1,940.99 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139891
Principal investigator 1 CIPLA USA INC. $3,813.48 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139897
Principal investigator 1 CIPLA USA INC. $1,188.00 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139903
Principal investigator 1 CIPLA USA INC. $387.19 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139909
Principal investigator 1 CIPLA USA INC. $387.19 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139935
Principal investigator 1 CIPLA USA INC. $387.19 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139941
Principal investigator 1 CIPLA USA INC. $1,891.45 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139947
Principal investigator 1 CIPLA USA INC. $263.83 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139953
Principal investigator 1 CIPLA USA INC. $387.19 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139959
Principal investigator 1 CIPLA USA INC. $387.19 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139965
Principal investigator 1 CIPLA USA INC. $263.83 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139971
Principal investigator 1 CIPLA USA INC. $387.19 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139977
Principal investigator 1 CIPLA USA INC. $1,517.17 10/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060139983
Principal investigator 1 Eli Lilly and Company $24,540.00 10/03/2023 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1038096635
Principal investigator 1 Eli Lilly and Company $226.65 09/26/2023 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1038090858
Principal investigator 1 PFIZER INC. $2,934.62 09/23/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046240179
Principal investigator 1 PFIZER INC. $33,031.44 09/15/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046242955
Principal investigator 1 GlaxoSmithKline, LLC. $9,780.30 09/13/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006263051
Principal investigator 1 PFIZER INC. $7,962.50 09/07/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046259739
Principal investigator 1 PFIZER INC. $41,912.52 08/24/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046010315
Principal investigator 1 GlaxoSmithKline, LLC. $16,573.50 08/16/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006263075
Principal investigator 1 PFIZER INC. $4,495.92 08/11/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046085043
Principal investigator 1 GlaxoSmithKline, LLC. $2,332.80 08/09/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1006263081
Principal investigator 1 Chiesi USA, Inc. $415.13 07/19/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051601225
Principal investigator 1 Chiesi USA, Inc. $6,120.51 07/19/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051601235
Principal investigator 1 GlaxoSmithKline, LLC. $5,843.70 07/12/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1006263063
Principal investigator 1 Eli Lilly and Company $22,973.00 06/27/2023 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1038108423
Principal investigator 1 PFIZER INC. $10,820.00 06/21/2023 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046316265
Principal investigator 1 GlaxoSmithKline, LLC. $3,948.30 06/14/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006263057
Principal investigator 1 Chiesi USA, Inc. $8,764.00 06/01/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051595709
Principal investigator 1 Chiesi USA, Inc. $5,962.40 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595341
Principal investigator 1 Chiesi USA, Inc. $6,120.51 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595343
Principal investigator 1 Chiesi USA, Inc. $2,492.08 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595345
Principal investigator 1 Chiesi USA, Inc. $415.13 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595347
Principal investigator 1 Chiesi USA, Inc. $415.13 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595349
Principal investigator 1 Chiesi USA, Inc. $1,214.73 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595351
Principal investigator 1 Chiesi USA, Inc. $2,492.08 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595353
Principal investigator 1 Chiesi USA, Inc. $1,214.73 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595355
Principal investigator 1 Chiesi USA, Inc. $2,492.08 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595357
Principal investigator 1 Chiesi USA, Inc. $415.13 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595359
Principal investigator 1 Chiesi USA, Inc. $6,120.51 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595361
Principal investigator 1 Chiesi USA, Inc. $1,214.73 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595363
Principal investigator 1 Chiesi USA, Inc. $5,962.40 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595365
Principal investigator 1 Chiesi USA, Inc. $5,962.40 05/22/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595367
Principal investigator 1 GlaxoSmithKline, LLC. $13,174.20 05/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006263045
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594883
Principal investigator 1 Chiesi USA, Inc. $6,120.51 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594885
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594887
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594889
Principal investigator 1 Chiesi USA, Inc. $6,120.51 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594891
Principal investigator 1 Chiesi USA, Inc. $6,120.51 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594893
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594895
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594897
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594899
Principal investigator 1 Chiesi USA, Inc. $6,120.51 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594901
Principal investigator 1 Chiesi USA, Inc. $415.13 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594903
Principal investigator 1 Chiesi USA, Inc. $2,492.08 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594905
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594907
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594909
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594911
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594913
Principal investigator 1 Chiesi USA, Inc. $5,962.40 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594915
Principal investigator 1 Chiesi USA, Inc. $415.13 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594917
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594919
Principal investigator 1 Chiesi USA, Inc. $415.13 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594921
Principal investigator 1 Chiesi USA, Inc. $1,214.73 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594923
Principal investigator 1 Chiesi USA, Inc. $415.13 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594925
Principal investigator 1 Chiesi USA, Inc. $6,120.51 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594927
Principal investigator 1 Chiesi USA, Inc. $415.13 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594929
Principal investigator 1 Chiesi USA, Inc. $6,120.51 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594931
Principal investigator 1 Chiesi USA, Inc. $1,776.59 05/11/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051594933
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593663
Principal investigator 1 Chiesi USA, Inc. $415.13 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593665
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593667
Principal investigator 1 Chiesi USA, Inc. $1,214.73 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593669
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593671
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593673
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593675
Principal investigator 1 Chiesi USA, Inc. $415.13 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593677
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593679
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593681
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593683
Principal investigator 1 Chiesi USA, Inc. $2,492.08 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593685
Principal investigator 1 Chiesi USA, Inc. $6,120.51 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593687
Principal investigator 1 Chiesi USA, Inc. $1,776.59 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593689
Principal investigator 1 Chiesi USA, Inc. $5,962.40 04/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593691
Principal investigator 1 CIPLA USA INC. $1,517.17 04/10/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060142857
Principal investigator 1 CIPLA USA INC. $387.19 04/10/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060142863
Principal investigator 1 Chiesi USA, Inc. $91,500.00 04/10/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051593065
Principal investigator 1 GlaxoSmithKline, LLC. $4,324.50 04/10/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006263033
Principal investigator 1 CIPLA USA INC. $1,891.45 03/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138415
Principal investigator 1 CIPLA USA INC. $1,940.99 03/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138433
Principal investigator 1 CIPLA USA INC. $3,813.48 03/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138549
Principal investigator 1 CIPLA USA INC. $387.19 03/17/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060142083
Principal investigator 1 GlaxoSmithKline, LLC. $32,804.10 03/15/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006263027
Principal investigator 1 CIPLA USA INC. $387.19 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138395
Principal investigator 1 CIPLA USA INC. $3,813.48 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138401
Principal investigator 1 CIPLA USA INC. $1,940.99 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138407
Principal investigator 1 CIPLA USA INC. $263.83 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138421
Principal investigator 1 CIPLA USA INC. $387.19 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138427
Principal investigator 1 CIPLA USA INC. $1,891.45 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138515
Principal investigator 1 CIPLA USA INC. $1,188.00 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138523
Principal investigator 1 CIPLA USA INC. $1,517.17 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138529
Principal investigator 1 CIPLA USA INC. $1,188.00 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138535
Principal investigator 1 CIPLA USA INC. $387.19 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060138541
Principal investigator 1 CIPLA USA INC. $387.19 03/08/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
Not supplied No dispute reported 06/30/2026 1060142077
Principal investigator 1 Eli Lilly and Company $4,607.04 01/31/2023 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1038097555
Principal investigator 1 Eli Lilly and Company $989.60 01/31/2023 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1038097883
Principal investigator 1 Eli Lilly and Company $461.54 01/26/2023 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY No dispute reported 06/30/2026 1038096623
Principal investigator 1 Eli Lilly and Company $228,397.00 01/24/2023 Non-covered Recipient Entity
EZY MEDICAL RESEARCH CO
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 1038096613
Principal investigator 1 GlaxoSmithKline, LLC. $218.70 01/04/2023 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1006263039